title: Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction.
abstract: BACKGROUND
  Left ventricular (LV) remodeling is a prognostically important development after acute myocardial infarction (AMI). We recently reported that vascular endothelial growth factor B (VEGFB) may be a potential new biomarker of LV remodeling. This potential biomarker was evaluated in the present study.
  
  
  RESULTS
  Patients with AMI (n = 290) and healthy volunteers (n = 42) were included. Plasma VEGFB levels were assessed before discharge. LV remodeling was determined by echocardiography at 6 months' follow-up. Levels of VEGFB were elevated in AMI patients compared with healthy volunteers (1.5-fold; P = .001). Mean plasma levels of VEGFB were 64% higher (P < .001) in patients in whom LV end-diastolic volume (EDV) decreased during follow-up (ΔEDV ≤ 0; n = 144; reverse remodeling) compared with patients in whom ΔEDV increased (ΔEDV > 0; n = 146; remodeling). Using logistic regression models, independent relationships were found between VEGFB (odds ratio [OR] 0.8, 95% confidence interval [CI] 0.7-0.9; P = .0007) and infarct territory (OR 1.7, 95% CI 1.1-2.8; P = .02). Patients with anterior MI and low levels of VEGFB had the highest risk of remodeling. VEFGB outperformed N-terminal pro-B-type natriuretic peptide to predict LV remodeling, and low levels of VEGFB (<100 pg/mL) provided a specificity of 90%. Adding VEGFB to a clinical model involving age, sex, smoking habit, and infarct territory resulted in a net reclassification index of 11.7%.
  
  
  CONCLUSIONS
  Plasma levels of VEGFB increase after AMI and correlate with preservation of cardiac function. Low levels of VEGFB accurately predict LV remodeling. Therefore, circulating VEGFB may have clinical utility in the identification of patients at high risk of remodeling after AMI.
authors.affiliation: Laboratory of Cardiovascular Research, Luxembourg, Luxembourg. yvan.devaux@crp-sante.lu
authors.forename: Yvan
authors.initials: Y
authors.lastname: Devaux
authors.forename: Melanie
authors.initials: M
authors.lastname: Vausort
authors.forename: Francisco
authors.initials: F
authors.lastname: Azuaje
authors.forename: Michel
authors.initials: M
authors.lastname: Vaillant
authors.forename: Marie-Lise
authors.initials: ML
authors.lastname: Lair
authors.forename: Etienne
authors.initials: E
authors.lastname: Gayat
authors.forename: Johan
authors.initials: J
authors.lastname: Lassus
authors.forename: Leong L
authors.initials: LL
authors.lastname: Ng
authors.forename: Dominic
authors.initials: D
authors.lastname: Kelly
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Wagner
authors.forename: Iain B
authors.initials: IB
authors.lastname: Squire
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000503:physiopathology*; D011379:Prognosis; D012372:ROC Curve; D012680:Sensitivity and Specificity; D042561:Vascular Endothelial Growth Factor B / Q000502:physiology*; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: D015415:Biomarkers; D042561:Vascular Endothelial Growth Factor B